Pacira BioSciences (PCRX) Cash from Investing Activities (2010 - 2026)

Pacira BioSciences' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at $19.4 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 175.86% year-over-year to $19.4 million; the TTM figure through Mar 2026 stood at $144.6 million (up 254.81% YoY), while the FY2025 annual figure was $99.5 million, up 219.46% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $19.4 million, up from $19.3 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $66.2 million in Q1 2023, with the low at -$208.0 million in Q1 2022.
• The 5-year median for Cash from Investing Activities is $7.3 million (2023), against an average of -$6.6 million.
• The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities slumped 1101.36% in 2024, then soared 5353.53% in 2025.
• Pacira BioSciences' Cash from Investing Activities stood at $11.2 million in 2022, then dropped by 25.16% to $8.4 million in 2023, then slumped by 104.39% to -$368000.0 in 2024, then jumped by 5353.53% to $19.3 million in 2025, then climbed by 0.56% to $19.4 million in 2026.
• Business Quant data shows PCRX's Cash from Investing Activities at $19.4 million in Q1 2026, $19.3 million in Q4 2025, and $43.6 million in Q3 2025.